CAMBRIDGE, Mass. — April 11, 2022 — Lucy Therapeutics (LucyTx), a biotech with a unifying mitochondrial platform, today announced it secured funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), the largest nonprofit funder of Parkinson’s disease research. The grant, valued at $4.9 million, will be used for continued investment into LucyTx’s mitochondrial platform, including the development of potential novel medicines.
Lucy Therapeutics Receives $4.9 Million Grant from Michael J. Fox Foundation
The latest from our portfolio companies that are changing the world.
Drilling 12 Miles Down to Tap Geothermal Energy
Most geothermal power today comes from natural geysers or drilling operations that plunge a few miles down to harness heat from buried rock. Quaise Energy, a startup based in Boston, is taking a third approach: digging deeper—and using more heat—than any company has...
Safar Partners is committed to funding technological advances that create value.
Interested in partnering with us?
One Broadway, 14th floor,
Cambridge, MA 02142